Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.55 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938009 | 0.85 | BACE1 (0.49) | BACE1NOS1NOS2KCNH2HTR7 | |
| SCHEMBL4937539 | 0.85 | BACE1 (0.73) | BACE1NOS1NOS2DHFRMAOB | |
| SCHEMBL14034461 | 0.83 | NOS1 (0.54) | BACE1NOS1NOS2DHFRNOS3 | |
| SCHEMBL4142172 | 0.71 | BACE1 (1.00) | BACE1 | |
| SCHEMBL4149077 | 0.70 | BACE1 (0.97) | BACE1 | |
| SCHEMBL4134277 | 0.70 | BACE1 (0.79) | BACE1 | |
| SCHEMBL4939874 | 0.70 | BACE1 (0.65) | BACE1DHFRMAOB | |
| SCHEMBL24629256 | 0.70 | MAOA (0.51) | BACE1NOS1NOS2HTR7FFAR1 | |
| SCHEMBL3836772 | 0.69 | AGXT (0.48) | BACE1KCNH2HTR7AGXTMAOA | |
| SCHEMBL4533749 | 0.68 | AGXT (0.52) | BACE1HTR7AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | BACE1 30/4885NOS1 269/4885NOS2 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.